So at a minimum we would perhaps expect a "Cellceutix is pleased to announce that the first administered doses of Kevetrin were well received by the first cohort and no dose limiting occurrences exist at this point in the study." Or something like that, eh? I'll take that - that is a positive as you say. I'm so curious as to the possibility of receiving even that PR. I can wait... I guess. Amazing how even a year later my interest continues to grow.
News 
Market Data 
Discover 
